Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Pedro M Rodrigues

Showing results (101-110 of 112) with videos related to

Pageof 12
Sort By:
Cells|March 19, 2020
Patients with Cholangiocarcinoma Present Specific RNA Profiles in Serum and Urine Extracellular Vesicles Mirroring the Tumor Expression: Novel Liquid Biopsy Biomarkers for Disease DiagnosisAinhoa Lapitz, Ander Arbelaiz, Colm J O'Rourke, et al.
Hepatology (Baltimore, Md.)|February 11, 2025
Targeting protein hyper-SUMOylation halts cholangiocarcinoma progression by impairing cancer cell viability and tumor-stroma cross talkPaula Olaizola, Irene Olaizola, Marta Fernandez de Ara, et al.
Journal of Hepatology|May 5, 2025
New platinum derivatives selectively cause double-strand DNA breaks and death in naïve and cisplatin-resistant cholangiocarcinomasIrene Olaizola, Mikel Odriozola-Gimeno, Paula Olaizola, et al.
Nature Reviews. Gastroenterology & Hepatology|July 2, 2020
Cholangiocarcinoma 2020: the next horizon in mechanisms and managementJesus M Banales, Jose J G Marin, Angela Lamarca, et al.
Nature Reviews. Gastroenterology & Hepatology|February 9, 2023
Criteria for preclinical models of cholangiocarcinoma: scientific and medical relevanceDiego F Calvisi, Luke Boulter, Javier Vaquero, et al.
Nature Reviews. Gastroenterology & Hepatology|December 10, 2025
Cholangiocarcinoma 2026: status quo, unmet needs and prioritiesJesus M Banales, Pedro M Rodrigues, Silvia Affò, et al.
Journal of Hepatology|March 3, 2023
Liquid biopsy-based protein biomarkers for risk prediction, early diagnosis, and prognostication of cholangiocarcinomaAinhoa Lapitz, Mikel Azkargorta, Piotr Milkiewicz, et al.
Hepatology (Baltimore, Md.)|July 28, 2025
E2F2 transcription factor promotes a cholestatic MASH phenotype by regulating hepatobiliary metabolism through miR-34a-5pMaider Apodaka-Biguri, André L Simão, Francisco González-Romero, et al.
Hepatology (Baltimore, Md.)|June 13, 2025
Refinement of histologic subtypes and identification of biomarkers linked to unfavorable prognosis in cholangiocarcinoma: The ENSCCA registries' framework for digital twin advancementGuido Carpino, Diletta Overi, Rocio Ir Macias, et al.
Gut|August 5, 2025
Role of CNNM4 in the progression of cholangiocarcinoma: implications for ferroptosis and therapeutic potentialMaria Mercado-Gómez, Naroa Goikoetxea-Usandizaga, Alvaro Eguileor Giné, et al.
Pageof 12

Showing results (101-110 of 112) with videos related to

Sort By:
Pageof 12
Cells|March 19, 2020
Patients with Cholangiocarcinoma Present Specific RNA Profiles in Serum and Urine Extracellular Vesicles Mirroring the Tumor Expression: Novel Liquid Biopsy Biomarkers for Disease DiagnosisAinhoa Lapitz, Ander Arbelaiz, Colm J O'Rourke, et al.
Hepatology (Baltimore, Md.)|February 11, 2025
Targeting protein hyper-SUMOylation halts cholangiocarcinoma progression by impairing cancer cell viability and tumor-stroma cross talkPaula Olaizola, Irene Olaizola, Marta Fernandez de Ara, et al.
Journal of Hepatology|May 5, 2025
New platinum derivatives selectively cause double-strand DNA breaks and death in naïve and cisplatin-resistant cholangiocarcinomasIrene Olaizola, Mikel Odriozola-Gimeno, Paula Olaizola, et al.
Nature Reviews. Gastroenterology & Hepatology|July 2, 2020
Cholangiocarcinoma 2020: the next horizon in mechanisms and managementJesus M Banales, Jose J G Marin, Angela Lamarca, et al.
Nature Reviews. Gastroenterology & Hepatology|February 9, 2023
Criteria for preclinical models of cholangiocarcinoma: scientific and medical relevanceDiego F Calvisi, Luke Boulter, Javier Vaquero, et al.
Nature Reviews. Gastroenterology & Hepatology|December 10, 2025
Cholangiocarcinoma 2026: status quo, unmet needs and prioritiesJesus M Banales, Pedro M Rodrigues, Silvia Affò, et al.
Journal of Hepatology|March 3, 2023
Liquid biopsy-based protein biomarkers for risk prediction, early diagnosis, and prognostication of cholangiocarcinomaAinhoa Lapitz, Mikel Azkargorta, Piotr Milkiewicz, et al.
Hepatology (Baltimore, Md.)|July 28, 2025
E2F2 transcription factor promotes a cholestatic MASH phenotype by regulating hepatobiliary metabolism through miR-34a-5pMaider Apodaka-Biguri, André L Simão, Francisco González-Romero, et al.
Hepatology (Baltimore, Md.)|June 13, 2025
Refinement of histologic subtypes and identification of biomarkers linked to unfavorable prognosis in cholangiocarcinoma: The ENSCCA registries' framework for digital twin advancementGuido Carpino, Diletta Overi, Rocio Ir Macias, et al.
Gut|August 5, 2025
Role of CNNM4 in the progression of cholangiocarcinoma: implications for ferroptosis and therapeutic potentialMaria Mercado-Gómez, Naroa Goikoetxea-Usandizaga, Alvaro Eguileor Giné, et al.
Pageof 12